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MaOBJECTIVES This study sought to evaluate the optimal percutaneous coronary intervention techniques using drug-
eluting stents for bifurcation coronary lesions.
BACKGROUND The optimal bifurcation stenting technique needs to be evaluated.
METHODS The trial included 2 randomization studies separated by the presence of side branch (SB) stenosis for patients
having non–left main bifurcation lesions. For 306 patients without SB stenosis, the routine ﬁnal kissing balloon or leave-
alone approaches were compared. Another randomization study compared the crush or single-stent approaches for
419 patients with SB stenosis.
RESULTS Between the routine ﬁnal kissing balloon and leave-alone groups for nondiseased SB lesions, angiographic
restenosis occurred in 17.9% versus 9.3% (p ¼ 0.064), comprising 15.1% versus 3.7% for the main branch (p ¼ 0.004)
and 2.8% versus 5.6% for the SB (p ¼ 0.50) from 214 patients (69.9%) receiving 8-month angiographic follow-up.
Incidence of major adverse cardiac events including death, myocardial infarction, or target vessel revascularization over
1 year was 14.0% versus 11.6% between the routine ﬁnal kissing balloon and leave-alone groups (p ¼ 0.57). In another
randomization study for diseased SB lesions, 28.2% in the single-stent group received SB stents. From 300 patients
(71.6%) receiving angiographic follow-up, between the crush and single-stent groups, angiographic restenosis rate was
8.4% versus 11.0% (p ¼ 0.44), comprising 5.2% versus 4.8% for the main branch (p ¼ 0.90) and 3.9% versus 8.3% for
the SB (p ¼ 0.12). One-year major adverse cardiac events rate between the crush and single-stent groups was 17.9%
versus 18.5% (p ¼ 0.84).
CONCLUSIONS Angiographic and clinical outcomes were excellent after percutaneous coronary intervention using
drug-eluting stents with any stent technique for non–left main bifurcation lesions once the procedure was performed
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551AB BR E V I A T I O N S
AND ACRONYM S
DES = drug-eluting stent
FKB = ﬁnal kissing balloon
IVUS = intravascular
ultrasound
MACE = major adverse
cardiac events
MB = main branch
MI = myocardial infarction
PCI = percutaneous
coronary intervention
SB = side branch
TIMI = Thrombolysis In
Myocardial InfarctionA mong the percutaneous coronary interven-tion (PCI) techniques proposed for drug-eluting stents (DES), the optimal stenting
technique for bifurcation coronary lesions is still un-
der debate (1). Most clinical trials, such as CACTUS
(Coronary Bifurcations: Application of the Crushing
Technique Using Sirolimus-Eluting Stents) (2),
NORDIC (Nordic Bifurcation Stent Technique Study)
I, II, and III (3–5), and BBC ONE (British Bifurcation
Coronary Study) (6), failed to show the superior out-
comes of a unique stent technique over others. These
studies were also limited in generalizability due to
the heterogeneity of the inclusion criteria, operator
experience, study protocol, and enrolled population
across the studies.SEE PAGE 561To enhance our understanding for bifurcation in-
terventions, we planned a trial to enroll all bifurcation
lesions whether they have side branch (SB) stenosis or
not. However, due to the varying indications of diverse
stenting techniques, a single randomization study
could not possess multiple comparisons. Therefore,
we designed a trial consisting of 2 parallel randomi-
zation studies separated according to the presence of
SB stenosis. The 2 randomizations were nominated as
different abbreviated names to highlight different in-
dications and interventional approaches. This study,
therefore, consecutively enrolled all potential candi-
dates having non–left main bifurcation lesions with or
without SB stenosis at the same sites by the same in-
vestigators. One study of the trial was the CROSS
(Choice of Optimal Strategy for Bifurcation Lesions
With Normal Side Branch) study, which compared the
role of routine ﬁnal kissing balloon (FKB) inﬂation to
the selective use of FKB for bifurcations without SB
stenosis. The PERFECT (Optimal Stenting Strategy for
True Bifurcation Lesions) study was the other study,
which compared the crush technique to the single-
stent technique for bifurcations with SB stenosis.
METHODS
STUDY DESIGN. The trial consisted of the randomi-
zation studies of the CROSS and PERFECT studies,
which were prospective, open-label, randomized
studies conducted in 14 centers across Korea. The 2
parallel studies were designed to include all comers of
patients having bifurcation coronary lesions with or
without SB stenosis from the same investigating sites.
Patients were eligible for the studies if they were 18 to
75 years old and had angina with bifurcation coronary
disease requiring protection, with a reference diam-
eter $2.5 mm in the main branch (MB), a lesion length#50mm, and a reference diameter$2.0mm in
the SB. Exclusion criteria were left main dis-
ease, in-stent restenosis, graft lesions, chronic
total occlusion, ST-segment elevation myo-
cardial infarction (MI) within 2 weeks,
decreased SB ﬂow, renal failure, left ventric-
ular ejection fraction #35%, and serious
comorbidities with a life expectancy<1 year. If
patients met the inclusion criteria, SB stenosis
by visual estimation determined potential in-
clusion in the CROSS study for patientswith SB
stenosis <50% or in the PERFECT study, for
patients with SB stenosis $50% and a lesion
length <20 mm. All patients provided written
informed consent. The study was approved
by the Institutional Review Board at each
hospital.
Study participants were randomly assigned to the
stenting technique groups in a 1:1 ratio, using an
interactive web-based response system. For the
CROSS study, after MB stenting, patients with SB
stenosis $50% and good ﬂow and those with TIMI
(Thrombolysis In Myocardial Infarction) ﬂow grade 3
were randomly assigned to either the routine FKB or
the leave-alone group as shown in Figure 1. Patients
with SB stenosis <50% or decreased TIMI ﬂow grade
#2 after MB stenting were not randomized but were
referred to the registry group. For the PERFECT study,
after successful wire placement in both the MB and SB,
patients were randomized to the crush and single-
stent technique groups. The randomization sequence
was computer-generated and stratiﬁed according to
the participating center and stent type used.
STENTING TECHNIQUES. All procedures were per-
formed using standard techniques for PCI (7). Intra-
vascular ultrasound (IVUS) evaluation of both
branches was recommended for all patients. To
standardize the stenting techniques, the study pro-
tocol speciﬁed procedural steps for each stenting
technique as shown in Online Figure 1. Pre-dilation of
the SB was not recommended in the CROSS study, but
it was performed at the discretion of the operator in
the PERFECT study. For patients in the CROSS study,
FKB was routinely performed in the routine FKB
group but discouraged in the leave-alone group.
Fractional ﬂow reserve was used to assess functional
ischemia in the MB at the discretion of the operator.
Because the purpose of the study was to assess the
outcome of routine FKB, fractional ﬂow reserve for
the SB was not used to guide the procedure. If the
SB showed decreased ﬂow, serious dissection, or
suboptimal results with stenosis $70% after FKB,
provisional-T stenting was selectively performed (8).
FIGURE 1 Study Flow
The ﬂow chart depicts how patients were assigned to the registry and studies and how the studies were randomized. *$2mm diameter and
$50% stenosis. CROSS ¼ Choice of Optimal Strategy for Bifurcation Lesions With Normal Side Branch; FKB ¼ ﬁnal kissing balloon; PERFECT ¼
Optimal Stenting Strategy for True Bifurcation Lesions; SB ¼ side branch; TIMI ¼ Thrombolysis In Myocardial Infarction.
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552In the PERFECT study, stenting with the crush
technique was performed as previously described
(8,9). In brief, before SB crushing, the SB stent was
minimally retracted to the MB to avoid excessive
overlap ofmetal struts in the proximal MB. Crushing of
the SB stent was performed with an MB stent or
balloon. In the single-stent group, when a serious SB
complication occurred after pre-dilation, the patient
was moved to the crush group to receive SB stenting
ﬁrst. For stent optimization, FKB was routinely at-
tempted in all patients who underwent 2-stent tech-
niques, such as crush or provisional-T. During crush
stenting, 2-step FKB, in which post-dilations in the SB
and MB were followed by FKB, was performed (10).
Antithrombotic therapy consisted of standard dual
antiplatelet therapy with 100 mg/day of aspirin and
75 mg/day of clopidogrel for at least 12 months after
all procedures.
STUDY ENDPOINTS ANDANGIOGRAPHIC EVALUATION.
The primary endpoints of the CROSS and PERFECT
studies were in-segment percentage diameter stenosison the SB and overall restenosis rate on bothMB and SB
at the 8-month angiography, respectively. Therefore,
all patients were asked to receive an angiographic
follow-up at 8 months post-procedure or earlier if
angina symptoms occurred. Quantitative angiographic
analysis of the MB and SB were performed within the
stented segment (in-stent) and over the entire segment
(in-segment), including the stent and within 5 mm of
the proximal and distal margins in an angiographic
core laboratory of the CardioVascular Research Foun-
dation (Seoul, Korea) using dedicated bifurcation
angiographic software (CAAS-5.4, Pie Medical, Maas-
tricht, the Netherlands) (11). The reference diameter
was determined by interpolation. Binary restenosis
was deﬁned as $50% stenosis on follow-up angiog-
raphy. Bifurcation classiﬁcationsweremade according
to the Medina classiﬁcation (12).
CLINICAL FOLLOW-UP AND OUTCOMES. Clinical
follow-up was performed at 1, 3, 6, and 12 months,
and annually thereafter for 5 years. The clinical end-
points were major adverse cardiac events (MACE)
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553comprising death, MI, and target vessel revasculari-
zation with its individual components. Deaths were
considered cardiac unless an unequivocal, noncardiac
cause was established. MI was deﬁned as an increase
in creatine kinase-myocardial band concentration
to >3 the upper limit of the normal range, with
ischemic symptoms or new ischemic electrocardio-
graphic changes. Target lesion revascularization was
deﬁned as repeat revascularization with PCI or coro-
nary artery bypass surgery for restenosis of the entire
segment involving the implanted stent and within
5 mm of the distal and proximal margins of the stent.
Target vessel revascularization was deﬁned as any
repeat revascularization in the treated vessel and was
considered clinically driven when the treated vessels
had at least 50% stenosis in the presence of ischemic
signs or symptoms.
STATISTICAL ANALYSIS. The primary analysis in the
CROSS study was a noninferiority comparison be-
tween routine FKB and leave-alone groups for the
primary endpoint. Angiographic in-segment percent-
age diameter stenosis on the SB was the primary
endpoint and was assumed to be 30% in the routine
FKB group (13,14). The sample size of 90 randomized
patients in each group was calculated with a non-
inferiority margin of 15% and a statistical power of
90%, a 1-sided signiﬁcant alpha of 0.05, and a follow-
up loss of 20%. For the PERFECT study, the hypoth-
esis was that the crush technique was superior to the
single-stent technique in terms of the overall reste-
nosis rate of the MB or SB at the 8-month angio-
graphic follow-up. A sample size of 240 patients in
each group was calculated with the assumption of an
overall restenosis rate of 11% in the crush group and
23% in the provisional-T stent group, a power of 90%,
a drop-out of 15%, and a 2-sided signiﬁcant alpha of
0.025 (2,15,16). After reaching 90% of the target
number in the PERFECT study, the data safety
monitoring board decided to terminate the study due
to a delay in enrollment. Because the 2 parallel
studies were performed during the same study
period, 306 and 419 patients were ﬁnally enrolled in
the CROSS and PERFECT studies between April 2007
and January 2013, respectively (Figure 1).
All analyses were performed in accordance with an
intention-to-treat principle. Differences in baseline
clinical, angiographic, and procedural characteristics
were compared using the Student t test for con-
tinuous variables and the chi-square or Fisher exact
test for categorical variables, as appropriate. The
Kaplan-Meier method was used to estimate survival
rates in the 2 groups. For clinical endpoints, pa-
tients were censored at 1 year or when the endpointoccurred. SAS software (version 9.1, SAS Institute,
Cary, North Carolina) was used for statistical
analyses.
RESULTS
STUDY POPULATION. Baseline clinical characteris-
tics were well matched between the 2 treatment
groups in the CROSS and PERFECT studies (Table 1).
Procedural characteristics are shown in Table 2. The
majority of patients received IVUS guidance. There
was no difference in the type, number, and length of
the MB stents between the 2 treatment groups in the
CROSS and PERFECT studies. SB stents were rarely
implanted in the CROSS study. In the PERFECT study,
28.2% of patients in the single-stent group received
SB stenting due to the suboptimal or impending oc-
clusion of SB. The incidence of peri-procedural MI
were 8.4% in the leave-alone and 5.3% in the routine
FKB groups in the CROSS study (p ¼ 0.29) and 14.1%
in the single-stent group and 14.1% in the crush
groups in the PERFECT study (p ¼ 0.98).
ANGIOGRAPHIC FINDINGS. Angiographic character-
istics at baseline and after the procedure are shown
in Table 3. Baseline angiographic characteristics
were similar between the 2 groups in the CROSS and
PERFECT studies. Signiﬁcant SB stenosis, which was
represented by a Medina classiﬁcation of 1.0.1., 1.1.1.,
0.1.1., or 0.0.1., was observed in 25.9% of patients in
the CROSS study and in 89.8% of patients in the
PERFECT study. After the procedure, for the MB, in-
stent minimal lumen diameter was comparable be-
tween the 2 treatment groups in the CROSS study, but
it was smaller in the crush group than in the single-
stent group in the PERFECT study. For the SB, ostial
minimal lumen diameter was greater in the routine
FKB group in the CROSS study and in the crush group
in the PERFECT study.
Follow-up angiography was performed in 214 pa-
tients (69.9%) in the CROSS study and 300 patients
(71.6%) in the PERFECT study as shown in Table 4.
For the primary endpoints, in the CROSS study,
8-month in-segment percentage SB stenosis was not
inferior in the leave-alone group compared with that
of the routine FKB group (p for noninferiority < 0.001
and superiority ¼ 0.074). Overall angiographic reste-
nosis in analysis segment, as the primary endpoint of
the PERFECT study, was not different between the
crush and the single-stent groups. In the MB, the in-
segment restenosis rate was higher in the routine
FKB group than in the leave-alone group in the CROSS
study, but it was comparable between the 2 groups in
the PERFECT study. The in-segment SB restenosis
rate was comparable between the 2 treatment groups
TABLE 1 Baseline Characteristics of Patients
CROSS Study PERFECT Study
Routine-FKB
(n ¼ 151)
Leave-Alone
(n ¼ 155) p Value
Crush
(n ¼ 213)
Single-Stent
(n ¼ 206) p Value
Age, yrs 61.0  9.2 61.0  7.9 0.98 60.9  8.9 61.1  8.8 0.86
Male 107 (70.9) 104 (67.1) 0.48 160 (75.1) 155 (75.2) 1.0
Body mass index, kg/m2 24.7  3.0 24.9  2.6 0.75 24.9  2.8 24.9  3.0 0.86
Current smoking 50 (33.1) 39 (25.2) 0.13 54 (25.4) 67 (32.5) 0.11
Diabetes mellitus 46 (30.5) 45 (29.0) 0.78 55 (25.8) 60 (29.1) 0.45
Hypertension 84 (55.6) 91 (58.7) 0.59 118 (55.4) 114 (55.3) 0.99
Hyperlipidemia 71 (47.0) 77 (49.7) 0.64 132 (62.0) 118 (57.3) 0.33
Family history of coronary disease 10 (6.6) 19 (12.3) 0.092 30 (14.1) 26 (12.6) 0.66
Previous coronary angioplasty 8 (5.3) 15 (9.7) 0.15 20 (9.4) 11 (5.3) 0.11
Renal dysfunction 4 (2.6) 0 (0.0) 0.058 1 (0.5) 1 (0.5) 1.0
Congestive heart failure 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.0) 0.24
Previous myocardial infarction 3 (2.0) 6 (3.9) 0.5 9 (4.2) 9 (4.4) 0.94
Clinical manifestation 0.64 0.43
Stable or asymptomatic angina 74 (49.0) 84 (54.2) 130 (61.3) 127 (62.0)
Unstable angina 66 (43.7) 62 (40.0) 74 (34.9) 65 (31.7)
Recent myocardial infarction 11 (7.3) 9 (5.8) 8 (3.8) 13 (6.3)
Left ventricular ejection fraction, % 60.9  7.0 62.2  5.7 0.098 60.4  6.8 59.5  7.2 0.2
Values are mean  SD or n (%).
CROSS ¼ Choice of Optimal Strategy for Bifurcation Lesions With Normal Side Branch; FKB ¼ ﬁnal kissing balloon; PERFECT ¼ Optimal Stenting Strategy for True Bifurcation
Lesions.
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location of restenosis according to the treatment
groups.
CLINICAL OUTCOMES. Table 5 shows the 1-year
clinical outcomes of patients. There was no differ-
ence in the rate of MACE and individual components
of MACE comprising death, MI, or target vessel
revascularization between the 2 treatment groups in
the CROSS and PERFECT studies. Figure 3 shows the
Kaplan-Meier incidence curves of 1-year MACE.
DISCUSSION
Our trial included 2 randomized studies evaluating
the optimal stent strategy for non–left main bifurca-
tion coronary lesions. They showed that any bifur-
cation stenting using current DES might achieve
excellent long-term results once the procedure is
performed successfully. In the CROSS study, for bi-
furcations without SB stenosis, the selective FKB
strategy was not inferior to routine FKB after MB
stenting for angiographic and clinical outcomes. For
true bifurcations with SB stenosis in the PERFECT
study, the crush technique failed to achieve better
angiographic outcomes than the single-stent tech-
nique did. Of interest, the 1-year incidence of death,
spontaneous MI, or target vessel revascularization
was in single-digit numbers in all groups in both
randomized studies.Because of different inclusion criteria of previous
randomization studies for bifurcation lesions, inter-
pretation of these comparative results should be done
carefully (2–6). It is common knowledge that out-
comes of bifurcation PCI are dependent on baseline
lesion complexity (17). In addition, due to the di-
versity of the bifurcation techniques proposed (18),
the study protocol must prespecify the individual
steps of the stenting techniques to assess the real
beneﬁts of each stenting technique. In this regard, we
stratiﬁed bifurcations into 2 different groups accord-
ing to the presence of baseline SB stenosis. We then
compared 2 commonly used stenting techniques for
each patient group of the CROSS and PERFECT study.
Moreover, to minimize the impact of procedural in-
homogeneity across operators, individual steps for
each stenting technique were detailed in the protocol
and approved by the operators (10). The use of
new-generation DES strengthened this study by rep-
resenting current practices of PCI compared with
previous randomized studies using ﬁrst-generation
DES (17,19). With the strengths, this report of a trial
including 2 randomized studies may help physicians
to understand the outcomes of diverse stenting
techniques.
In the CROSS study, enrolling bifurcations without
signiﬁcant SB stenosis, the selective use of FKB in the
leave-alone group was not inferior to the routine use
of FKB after MB stenting. In our study, although only
TABLE 2 Procedural Characteristics of Patients
CROSS Study PERFECT Study
Routine-FKB
(n ¼ 151)
Leave-Alone
(n ¼ 155) p Value
Crush
(n ¼ 213)
Single-Stent
(n ¼ 206) p Value
Treated vessels 0.54 0.62
1 111 (73.5) 109 (70.3) 159 (74.6) 145 (70.4)
2 35 (23.2) 43 (27.7) 46 (21.6) 52 (25.2)
3 5 (3.3) 3 (1.9) 8 (3.8) 9 (4.4)
Target bifurcation lesions 0.69 0.33
Left anterior descending artery 137 (90.7) 137 (88.4) 200 (93.9) 190 (92.2)
Left circumﬂex artery 11 (7.3) 12 (7.7) 10 (4.7) 15 (7.3)
Right coronary artery 3 (2.0) 6 (3.9) 3 (1.4) 1 (0.5)
Transradial approach 56 (37.1) 55 (35.5) 0.77 25 (11.7) 25 (12.1) 0.90
Procedure time, min 40.8  18.5 32.8  16.2 <0.001 52.5  21.0 48.7  21.2 0.065
Fluoroscopic time, min 21.4  10.3 17.9  8.1 0.001 29.3  14.1 25.9  12.7 0.013
Contrast amount, cc 287.4  127.7 273.3  110.4 0.31 349.6  145.0 347.0  124.5 0.85
Treatment of main branch
Noncompliant balloon 95 (62.9) 87 (56.1) 0.23 141 (66.2) 97 (47.1) <0.001
Cutting balloon 0 (0.0) 1 (0.6) 1.00 6 (2.8) 2 (1.0) 0.29
Intravascular ultrasound 139 (92.1) 149 (96.1) 0.13 204 (95.8) 197 (95.6) 0.94
Pre-dilation 148 (98.0) 149 (96.1) 0.50 208 (97.7) 202 (98.1) 1.0
Stent implantation 151 (100) 155 (100) 213 (100) 206 (100)
Number of stents 1.3  0.5 1.2  0.4 0.61 1.4  0.5 1.4  0.5 0.76
Mean stent diameter, mm 3.5  2.2 3.3  0.3 0.23 3.3  0.3 3.3  0.3 0.49
Length of stents, mm 33.2  13.1 33.0  14.8 0.94 37.3  14.7 36.9  15.3 0.76
Maximal pressure applied, atm 19.2  4.4 18.5  4.6 0.18 18.7  4.1 15.9  4.7 <0.001
Used stents 0.58 0.98
Sirolimus-eluting stents 47 (31.1) 36 (23.2) 127 (59.6) 118 (57.3)
Paclitaxel-eluting stents 17 (11.3) 21 (13.5) 2 (0.9) 3 (1.5)
Everolimus-eluting stents 33 (21.9) 36 (23.2) 59 (27.7) 59 (28.6)
Zotarolimus-eluting stents 44 (29.1) 53 (34.2) 19 (8.9) 19 (9.2)
Others 10 (6.6) 9 (5.8) 6 (2.8) 7 (3.4)
Treatment of side branch
Noncompliant balloon 18 (11.9) 2 (1.3) <0.001 116 (54.5) 26 (12.6) <0.001
Cutting balloon 0 (0.0) 1 (0.6) 1.00 2 (0.9) 0 (0.0) 0.50
Intravascular ultrasound 73 (48.3) 51 (32.9) 0.006 195 (91.5) 164 (79.6) <0.001
Pre-dilation 5 (3.3) 6 (3.9) 0.79 177 (83.1) 76 (36.9) <0.001
FKB inﬂation 144 (95.4) 7 (4.5) <0.001 204 (95.8) 163 (79.1) <0.001
Stent implantation 3 (2.0) 1 (0.6) 0.37 208 (97.7) 58 (28.2) <0.001
Number of stents 1 1 — 1.0  0.2 1.0  0.2 0.66
Mean stent diameter, mm 2.6  0.1 2.8 0.42 2.7  0.2 2.7  0.2 1.00
Length of stents, mm 24.7  2.9 30.0 0.25 21.4  6.7 21.5  6.9 0.93
Maximal pressure applied, atm 15.7  5.1 17.0 0.84 18.0  4.2 15.1  4.0 <0.001
Stenting technique 0.75 <0.001
Crush 0 (0.0) 0 (0.0) 206 (99.0) 15 (25.9)
Provisional-T 2 (66.7) 1 (100) 1 (0.5) 43 (74.1)
Others 1 (33.3) 0 (0.0) 1 (0.5) 0 (0.0)
Used stents 0.50 0.85
Sirolimus-eluting stents 2 (66.7) 0 (0.0) 126 (60.6) 34 (58.6)
Paclitaxel-eluting stents 0 (0.0) 0 (0.0) 2 (1.0) 0 (0.0)
Everolimus-eluting stents 1 (33.3) 0 (0.0) 54 (26.0) 19 (32.8)
Zotarolimus-eluting stents 0 (0.0) 1 (100) 18 (8.7) 4 (6.9)
Others 0 (0.0) 0 (0.0) 8 (3.8) 1 (1.7)
Values are n (%) or mean  SD. Dash indicates that data were unavailable.
Abbreviations as in Table 1.
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TABLE 3 Angiographic Characteristics of Lesions Before and After Procedure
CROSS Study PERFECT Study
Routine-FKB
(n ¼ 151)
Leave-Alone
(n ¼ 155) p Value
Crush
(n ¼ 213)
Single-Stent
(n ¼ 206) p Value
Baseline*
Medina classiﬁcation 0.18 0.012
1.0.0. 18 (12.2) 15 (9.8) 2 (1.0) 4 (2.0)
1.1.0. 52 (35.1) 74 (48.4) 5 (2.4) 22 (10.9)
1.0.1. 8 (5.4) 4 (2.6) 18 (8.7) 18 (8.9)
1.1.1. 28 (18.9) 24 (15.7) 137 (65.9) 126 (62.4)
0.1.0. 34 (23.0) 25 (16.3) 4 (1.9) 5 (2.5)
0.1.1. 6 (4.1) 4 (2.6) 39 (18.8) 25 (12.4)
0.0.1. 1 (0.7) 3 (2.0) 3 (1.4) 2 (1.0)
0.0.0. 1 (0.7) 4 (2.6) 0 (0.0) 0 (0.0)
Main branch
Severe calciﬁcation 7 (4.7) 8 (5.2) 0.84 25 (12.0) 25 (12.4) 0.91
Severe tortuosity 1 (0.7) 0 (0.0) 0.49 0 (0.0) 0 (0.0) —
TIMI ﬂow grade 0.14 0.43
0 or 1 4 (2.7) 5 (3.3) 3 (1.4) 6 (3.0)
2 4 (2.7) 0 (0.0) 14 (6.7) 10 (5.0)
3 140 (94.6) 148 (96.7) 191 (91.8) 186 (92.1)
Proximal reference diameter, mm 3.5  0.6 3.4  0.5 0.24 3.6  0.4 3.7  0.5 0.039
Distal reference diameter, mm 2.5  0.4 2.5  0.4 0.86 2.6  0.4 2.6  0.4 0.67
Lesion length, mm 28.3  12.9 27.1  12.8 0.42 28.9  14.6 27.8  13.1 0.43
Minimal lumen diameter, mm 1.2  0.4 1.1  0.4 0.20 1.1  0.4 1.1  0.4 0.75
Diameter stenosis, % 60.5  11.8 61.8  13.4 0.36 64.4  12.3 65.9  11.7 0.21
Side branch
Severe calciﬁcation 0 (0.0) 0 (0.0) — 5 (2.4) 4 (2.0) 1.0
Severe tortuosity 0 (0.0) 0 (0.0) — 0 (0.0) 1 (0.5) 0.49
TIMI ﬂow grade 0.84 1.0
0 or 1 2 (1.4) 4 (2.6) 1 (0.5) 1 (0.5)
2 1 (0.7) 1 (0.7) 16 (7.7) 15 (7.4)
3 145 (98.0) 148 (96.7) 191 (91.8) 186 (92.1)
Distal reference diameter, mm 2.1  0.4 2.1  0.4 0.069 2.2  0.4 2.2  0.4 0.17
Lesion length, mm 2.3  4.3 1.4  3.1 0.026 10.3  8.2 8.3  7.3 0.009
Minimal lumen diameter, mm 1.6  0.4 1.7  0.4 0.24 1.1  0.4 1.2  0.4 0.25
Diameter stenosis, % 29.4  13.4 29.0  15.7 0.82 57.2  14.5 53.3  16.5 0.012
Post-procedure*
Main branch
Stent length, mm 31.5  12.0 30.9  11.7 0.66 34.0  13.5 34.7  13.4 0.64
Minimal luminal diameter, mm
In-stent 2.6  0.4 2.6  0.4 0.68 2.6  0.4 2.7  0.4 0.041
In-segment 2.2  0.4 2.2  0.4 0.53 2.2  0.4 2.3  0.5 0.13
Diameter stenosis, %
In-stent 11.6  6.6 12.8  7.2 0.12 13.5  7.2 13.0  6.9 0.48
In-segment 20.3  8.7 20.7  8.3 0.70 22.1  10.0 20.7  8.7 0.12
Side branch
Stent length, mm 15.3  8.1 24.6 0.42 15.4  7.1 16.4  6.6 0.32
Minimal luminal diameter, mm
Ostium 1.7  0.4 1.6  0.5 0.053 2.3  0.4 1.9  0.6 <0.001
In-segment 1.6  0.4 1.5  0.4 0.15 1.8  0.4 1.6  0.4 <0.001
Diameter stenosis, %
Ostium 25.8  15.0 32.2  18.2 0.001 13.7  11.1 25.7  17.8 <0.001
In-segment 28.7  13.3 34.2  16.6 0.002 21.0  10.7 31.1  15.0 <0.001
Values are n (%) or mean  SD. Dashes indicate that data were unavailable. *Quantitative angiographic analysis in the core laboratory was available in 148 lesions (98.0%) in
the routine-FKB and 153 lesions (98.7%) in the leave-alone groups of the CROSS study and 208 lesions (97.7%) in the crush and 202 lesions (98.1%) in the single-stent groups
of the PERFECT study.
TIMI ¼ Thrombolysis In Myocardial Infarction; other abbreviations as in Table 1.
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TABLE 4 Angiographic Characteristics of Lesions at Follow-Up
CROSS Study PERFECT Study
Routine-FKB
(n ¼ 106)
Leave-Alone
(n ¼ 108) p Value
Crush
(n ¼ 155)
Single-Stent
(n ¼ 145) p Value
Overall restenosis, %* 19 (17.9) 10 (9.3) 0.064 13 (8.4) 16 (11.0) 0.44
Main branch
Minimal luminal diameter, mm
In-stent 2.2  0.6 2.3  0.5 0.32 2.4  0.4 2.4  0.5 1.0
In-segment 1.9  0.6 2.1  0.4 0.071 2.1  0.4 2.2  0.5 0.44
Diameter stenosis, %
In-stent 22.8  16.2 20.5  13.4 0.24 19.8  10.6 21.3  13.3 0.26
In-segment 29.7  17.3 25.7  13.1 0.064 26.8  13.1 26.1  12.4 0.65
Late luminal loss, mm
In-stent 0.4  0.5 0.3  0.4 0.13 0.2  0.3 0.3  0.4 0.036
In-segment 0.2  0.5 0.1  0.4 0.094 0.1  0.4 0.2  0.4 0.24
Restenosis
In-stent 8 (7.5) 1 (0.9) 0.018 2 (1.3) 5 (3.4) 0.27
Proximal edge 6 (5.7) 1 (0.9) 0.064 5 (3.2) 1 (0.7) 0.22
Distal edge 3 (2.8) 2 (1.9) 0.68 1 (0.6) 1 (0.7) 1.0
In-segment 16 (15.1) 4 (3.7) 0.004 8 (5.2) 7 (4.8) 0.90
Restenosis pattern 1.0 1.0
Focal 10 (62.5) 2 (50.0) 5 (62.5) 4 (57.1)
Diffuse 6 (37.5) 2 (50.0) 3 (37.5) 3 (42.9)
Side branch
Minimal luminal diameter, mm
Ostium 1.6  0.4 1.5  0.5 0.17 2.0  0.4 1.6  0.5 <0.001
In-segment 1.5  0.4 1.5  0.4 0.73 1.7  0.4 1.4  0.4 <0.001
Diameter stenosis, %
Ostium 27.5  15.9 33.3  16.9 0.010 23.2  15.1 34.3  18.9 <0.001
In-segment† 31.1  14.5 34.9  15.8 0.074 27.7  13.2 37.7  17.1 <0.001
Late luminal loss, mm
Ostium 0.1  0.4 0.1  0.4 0.59 0.3  0.4 0.3  0.5 0.15
In-segment 0.1  0.4 0.1  0.4 0.88 0.1  0.3 0.2  0.3 0.36
Restenosis
Ostium 2 (1.9) 4 (3.7) 0.68 1 (0.6) 4 (2.8) 0.20
In-segment 3 (2.8) 6 (5.6) 0.50 6 (3.9) 12 (8.3) 0.12
Restenosis pattern 0.33 0.52
Focal 2 (66.7) 6 (100) 6 (100) 9 (75.0)
Diffuse 1 (33.3) 0 (0.0) 0 (0.0) 3 (25.0)
Values are n (%) or mean  SD. *The primary endpoints of the PERFECT study. †The primary endpoints of CROSS study.
Abbreviations as in Table 1.
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5574.5% of patients ﬁnally received FKB in the leave-
alone group, angiographic and clinical outcomes
were excellent and comparable to those in patients
receiving routine FKB. On the other hand, MB reste-
nosis was higher in the routine FKB group due to the
potential distortion of the MB stent strut (20,21).
Otherwise, greater barotrauma in the MB due to FKB
might have resulted in more frequent restenosis at
the proximal part of stents in our study. Absence of
angiographic or clinical beneﬁts using routine FKB
was in line with the results of the NORDIC III study
(5). Previous studies evaluating ischemia of the SB
using fractional ﬂow reserve, partly explained the
mechanism by which a few SB after MB stenting werefunctionally compromised for bifurcations with
nondiseased SB (22–24). Given these results, in the
case of planned single-stent treatment for non–left
main bifurcation lesions, FKB needs to be conserva-
tively performed for selected patients with decreased
ﬂow or impending occlusion of the SB after MB
stenting.
The PERFECT study conﬁrmed the current
consensus that the single-stent technique yields
comparable clinical outcomes to the 2-stent tech-
nique (1). At follow-up angiography, the crush tech-
nique had no beneﬁts over the single-stent technique
in terms of angiographic and clinical restenosis.
Instead, the procedural time and contrast amount
FIGURE 2 Locations of Restenoses Between the 2 Treatments in the CROSS and PERFECT Studies
Locations of restenoses between the 2 treatments in the CROSS (A) and PERFECT (B) studies on an intention-to-treat analysis basis.
Abbreviations as in Figure 1.
TABLE 5 Clinical Outcomes of Patients
CROSS Study PERFECT Study
Routine-FKB
(n ¼ 151)
Leave-Alone
(n ¼ 155) p Value
Crush
(n ¼ 213)
Single-Stent
(n ¼ 206) p Value
Death 2 (1.3) 0 (0.0) 0.15 3 (1.4) 2 (1.0) 0.68
Cardiac 2 (1.3) 0 (0.0) 0.15 2 (0.9) 1 (0.5) 0.58
Noncardiac 0 (0.0) 0 (0.0) 1 (0.5) 1 (0.5) 0.98
Myocardial infarction 9 (6.0) 13 (8.4) 0.42 30 (14.1) 29 (14.1) 0.98
Q-wave 0 (0.0) 1 (0.6) 0.32 0 (0.0) 0 (0.0)
Non–Q-wave 9 (6.0) 12 (7.7) 0.55 30 (14.1) 29 (14.1) 0.98
Target vessel
revascularization
11 (7.4) 5 (3.2) 0.11 6 (2.9) 7 (3.4) 0.73
Clinically driven 4 (2.7) 1 (0.6) 0.16 1 (0.5) 3 (1.5) 0.30
Target lesion
revascularization
10 (6.7) 4 (2.6) 0.088 4 (1.9) 7 (3.4) 0.33
Percutaneous coronary
intervention
10 (6.7) 4 (2.6) 0.088 4 (1.9) 6 (2.9) 0.48
Main branch 9 (6.0) 3 (1.9) 0.067 4 (1.9) 6 (2.9) 0.48
Side branch 2 (1.3) 2 (1.3) 0.97 2 (1.0) 2 (1.0) 0.97
Coronary artery
bypass graft
0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 0.31
Main branch 0 (0.0) 1 (0.5) 0.31
Side branch 0 (0.0) 0 (0.0)
Stent thrombosis 0 (0.0) 1 (0.6) 0.33 1 (0.5) 0 (0.0) 0.32
Target lesion 0 (0.0) 0 (0.0) — 0 (0.0) 0 (0.0) —
Nontarget lesion 0 (0.0) 1 (0.6) 0.33 1 (0.5) 0 (0.0) 0.32
Major adverse
cardiac events
21 (14.0) 18 (11.6) 0.57 38 (17.8) 38 (18.5) 0.85
Values are n (%) using Kaplan-Meier methods. The p values were analyzed using the log-rank test. Dashes
indicate that data were unavailable.
Abbreviations as in Table 1.
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558used were signiﬁcantly greater after the crush tech-
nique. This ﬁnding was in line with previous
studies showing that the systemic use of the 2-stent
technique may not be appropriate, even for true
bifurcations (2,3,6,17). However, it should be noted
that 28% of patients in the single-stent group even-
tually received the 2-stent technique because of sub-
optimal results or impending occlusion of the SB
before or after MB stenting. This ﬁnding suggests that
the planned 2-stent technique can also be a reasonable
approach when SB occlusion is strongly anticipated.
When periprocedural MI was excluded, the 1-year
incidence of MACE was a single-digit number after
using any of the stent techniques in the CROSS and
PERFECT studies. Angiographic restenosis rates
ranged from 16.0% to 28.0% in the CACTUS (14) and
NORDIC (3) studies, but from 8.4% to 11.0% in our
PERFECT study. The low event rate may be partly due
to reﬁnement of the stenting technique with success-
ful performance or improved devices. For instance, in
our study, the systemic use of IVUS in more than 90%
of patients may have improved long-term clinical
outcomes for bifurcation coronary lesions (25). In
addition, after stent crushing, 95.8% of patients re-
ceived successful FKB, which may have subsequently
contributed to the low event rate (10,15). Recent use of
new-generation DES might also improve prognosis
(19). Given this ﬁnding, we can conclude that PCI for
FIGURE 3 Kaplan-Meier Incidence Curves of MACE in the CROSS and PERFECT Studies
Kaplan-Meier incidence curves of major adverse cardiac events (MACE) comprising death, myocardial infarction, or target vessel revasculari-
zation over 1 year in the CROSS (A) and PERFECT (B) studies on an intention-to-treat analysis basis. Abbreviations as in Figure 1.
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559bifurcation lesions using DES appears to lead to an
excellent prognosis once the procedure is performed
optimally, according to the standard guidelines.
STUDY LIMITATIONS. First, our studies were still
underpowered to compare clinical outcomes between
2 different treatments. Moreover, angiographic
follow-up was limitedly performed in 70% of pa-
tients. In particular, unexpectedly low restenosis
rate and early termination make a drawback of the
PERFECT study in the comparison of 2 stent tech-
niques. However, given the difﬁculty in enrolling
true bifurcations in randomized trials, comparably
low angiographic and clinical event rates between 2
stent techniques in the PERFECT study may still
provide valuable information. Second, due to the
unexpectedly long study enrollment period, there
might be temporal changes in the standard treat-
ments, such as use of DES and adjunctive medica-
tions. For instance, new-generation DES were used
for approximately one-half of the patients. Third,
although consecutive patients were prospectively
enrolled, not all patients with bifurcations were
recruited due to any reason. Moreover, because we
excluded patients with true bifurcations when
both wires could not be successfully inserted in the
MB and SB, it is likely that patients with very com-
plex bifurcation morphology were excluded from
our study. In addition, because enrollment was per-
formed by visual assessment of investigators, rela-
tively simple lesions were also included. True
bifurcations with diffuse SB stenosis were alsoexcluded. Therefore, event rates in our study may
have been under-reported compared with real-world
practices. Fourth, because SB diameter was rela-
tively small with the mean reference of 2.1 mm, bi-
furcations with big SB may have different outcomes.
Fifth, the outcomes of our studies may not be appli-
cable to all practices. The penetration rate of IVUS
during PCI is still <30% in the United States (26).
Finally, only 1 2-stent technique was evaluated in our
study. Other 2-stent techniques, such as culotte,
kissing, or a modiﬁed crush technique, may have a
different prognosis (18). However, given the previous
NORDIC II study, which showed comparable out-
comes between crush and culotte stenting, the ﬁnd-
ings of the PERFECT study may represent general
outcomes between single- and 2-stenting techniques.CONCLUSIONS
The CROSS and PERFECT studies demonstrated that
outcomes of PCI for bifurcation lesions were compa-
rably safe and effective with any stenting technique,
even for true bifurcation lesions. Of importance is
that the procedures must be done with a careful
functional and anatomical evaluation.
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PERSPECTIVES
The present cohort comprises 2 randomized trials—CROSS
and PERFECT—aimed to assess the outcomes of bifurca-
tion stenting with comparisons of diverse techniques
using new devices. The CROSS study highlighted that
routine ﬁnal kissing balloon inﬂation, which had been
considered necessary to restore the side branch ﬂow, may
lead to poor angiographic and subsequent clinical out-
comes due to higher restenosis rate in the main branch.
The PERFECT study indicated that either the double-stent
or single-stent technique with provisional side branch
treatment results in excellent clinical outcomes once the
procedure is optimally performed for true bifurcation le-
sions. Future research needs to investigate the optimized
technique or device for each individual patient.
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